AbbVie (NYSE: ABBV) will participate in the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026. Management will participate in a fireside chat at 10:10 a.m. Central Time.
AbbVie (NYSE: ABBV) will participate in the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026. Management will participate in a fireside chat at 10:10 a.m. Central Time.
SINGAPORE, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Ten-League International Holdings Limited (Nasdaq: TLIH) (the “Company” or “Ten-League”), a Singapore-based provider of turnkey project solutions, is pleased to announce the following financial guidance for Fiscal Year 2025. Fiscal Year 2025 refers to the 12-month period beginning on January 1, 2025, and ending on December 31, 2025.
SINGAPORE, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Ten-League International Holdings Limited (Nasdaq: TLIH) (the “Company” or “Ten-League”), a Singapore-based provider of turnkey project solutions, is pleased to announce the following financial guidance for Fiscal Year 2025. Fiscal Year 2025 refers to the 12-month period beginning on January 1, 2025, and ending on December 31, 2025.
Stripe Inc. , which helps businesses accept payments online, has reached a $159 billion valuation in an employee tender offer, co-founder and president John Collison said in an interview. That valuation is up from the $106.7 billion Stripe secured last year, underscoring its staying power as one of fintech’s most valuable companies even as it keeps investors waiting for any public market debut. Th...
Stripe Inc. , which helps businesses accept payments online, has reached a $159 billion valuation in an employee tender offer, co-founder and president John Collison said in an interview. That valuation is up from the $106.7 billion Stripe secured last year, underscoring its staying power as one of fintech’s most valuable companies even as it keeps investors waiting for any public market debut. There are no imminent plans for a public listing, Collison said. The latest valuation estimate comes as the company said it processed $1.9 trillion in total payment volume in 2025, up 34% from the year before, according to its annual letter published Tuesday. “We’re really seeing Stripe be the preferred vendor for anyone building AI applications or all these fast-growing applications,” Collison said. “We’re simultaneously winning a lot of share in the enterprise market,” adding that companies like Microsoft Corp. and Nvidia Corp. are switching to Stripe. Read more: Stripe Valuation Set to Hit $140 Billion in New Tender Offer Stripe said it remained profitable last year while continuing to invest heavily in product development and acquisitions. The company recently bought stablecoin orchestration platform Bridge and crypto wallet provider Privy as it expands deeper into crypto-related payments. The stablecoin payment market volume doubled to about $400 billion last year, Stripe said, with roughly 60% of that estimated to be business-to-business transactions. Bridge’s volume more than quadrupled over the same period, according to the letter. To handle higher stablecoin activity, Stripe unveiled its own blockchain, Tempo, incubated with crypto venture firm Paradigm. Tempo is designed for stablecoin payments and aims to avoid fee spikes and processing delays during periods of heavy traffic — including an episode last year when a memecoin trading surge delayed payouts for one Bridge customer by more than 12 hours, Stripe wrote. Stripe in January said it acquired Metronome, which p...
Railroad freight remains a critical but often overlooked backbone of the economy, even as uncertainty clouds capital investment decisions. Railcar orders have moderated amid tariff concerns and cautious shipper spending, yet Greenbrier’s backlog remains strong, underscoring resilient underlying demand. In this Talking Transports podcast, Greenbrier CEO Lorie Tekorius joins Bloomberg Intelligence’s...
Railroad freight remains a critical but often overlooked backbone of the economy, even as uncertainty clouds capital investment decisions. Railcar orders have moderated amid tariff concerns and cautious shipper spending, yet Greenbrier’s backlog remains strong, underscoring resilient underlying demand. In this Talking Transports podcast, Greenbrier CEO Lorie Tekorius joins Bloomberg Intelligence’s Lee Klaskow to discuss the company’s strategy to balance cyclical new railcar manufacturing with ex
The US remains central to AI leadership, but investors should expect broader, more global opportunities to emerge in 2026. In this episode of the Inside Active podcast, host David Cohne, mutual fund and active management analyst at Bloomberg Intelligence, and co-host Breanne Dougherty, BI’s head of thematic strategy, speak with Sarbjit Nahal, a portfolio manager and analyst with the Global Themati...
The US remains central to AI leadership, but investors should expect broader, more global opportunities to emerge in 2026. In this episode of the Inside Active podcast, host David Cohne, mutual fund and active management analyst at Bloomberg Intelligence, and co-host Breanne Dougherty, BI’s head of thematic strategy, speak with Sarbjit Nahal, a portfolio manager and analyst with the Global Thematic Equity team at Lazard Asset Management, which manages the Lazard Equity Megatrends ETF (THMZ). The
OAK BROOK, Ill., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Portillo’s Inc. (“Portillo’s” or the “Company”) (NASDAQ: PTLO), the one-of-a-kind restaurant concept known for its menu of Chicago-style favorites, today reported financial results for the fourth quarter and fiscal year ended December 28, 2025.
OAK BROOK, Ill., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Portillo’s Inc. (“Portillo’s” or the “Company”) (NASDAQ: PTLO), the one-of-a-kind restaurant concept known for its menu of Chicago-style favorites, today reported financial results for the fourth quarter and fiscal year ended December 28, 2025.
Victor Golmer/iStock Editorial via Getty Images I continue to mark a Buy rating for Tesla, Inc. ( TSLA ) stock based on its aggressive, capital-intensive formation into a vertically integrated physical AI utility. My current thesis depends on the progressive closure of the Energy-Compute-Labor loop. The loop is utilizing record-breaking energy storage margins to fund the massive $20 billion 2026 C...
Victor Golmer/iStock Editorial via Getty Images I continue to mark a Buy rating for Tesla, Inc. ( TSLA ) stock based on its aggressive, capital-intensive formation into a vertically integrated physical AI utility. My current thesis depends on the progressive closure of the Energy-Compute-Labor loop. The loop is utilizing record-breaking energy storage margins to fund the massive $20 billion 2026 CapEx cycle needs for the Cortex 2 AI cluster, the domestic Terafab for chips, and the Cybercab ramp. The move to terminate Model S and X production to retool Fremont for 1 million annual Optimus units is, in my opinion, a decisive shift toward a total addressable market far more expanded than transportation. For the Buy Tesla stock thesis, major risks include the Hardware-AI Capital Intensity Trap (as rising depreciation from semiconductor and robotics manufacturing outpaces revenue growth) and the regulatory issues from the OBBBA legislation that has already impacted margins through tariff increases and tax credit repeals. My previous coverage (December 2025) rated Tesla a Prudent Buy and was focused on the surging Energy segment that is decoupling from automotive cyclicality to offset shrinking EV margins. The last article identified Megablock scaling as the primary valuation support amid profitless growth in EVs. This current analysis progresses by integrating the January 2026 confirmation of the Energy-Compute-Labor loop. This thesis moves beyond simple margin analysis to focus on the aggressive decommissioning of legacy auto lines (Model S/X) for Optimus and the solvency risks of the $20 billion Hardware-AI CapEx cycle. The article is redefining Tesla as a vertically integrated physical AI utility beyond an energy-backed EV maker. The Mergence Of The Energy-Compute-Labor Loop The forward bullish catalyst for Tesla’s stock price (over the long term) is expanded to the possible progressive closure of the Energy-Compute-Labor loop. The loop can build a vertically integrat...
Series B, with participation from Databricks Ventures and others, to fuel continued product innovation in unlocking live, verifiable web data with enterprise-scale accuracy and completeness NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Nimble, the only real-time web search and data platform that’s trusted by hundreds of enterprises, today announced $47 million in Series B financing, bringing its tot...
Series B, with participation from Databricks Ventures and others, to fuel continued product innovation in unlocking live, verifiable web data with enterprise-scale accuracy and completeness NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Nimble, the only real-time web search and data platform that’s trusted by hundreds of enterprises, today announced $47 million in Series B financing, bringing its total funding to $75 million. The round was led by Norwest, with participation from Databricks Ventures
Nimble uses AI agents to search the web, verify and validate the results, and then clean and structure the information into neat tables that can then be queried like a database.
Nimble uses AI agents to search the web, verify and validate the results, and then clean and structure the information into neat tables that can then be queried like a database.
Shidlovski/iStock via Getty Images Larimar Therapeutics ( LRMR ) added ~38% in the premarket on Tuesday after the rare disease drug developer said that the U.S. FDA has granted Breakthrough Therapy Designation for its lead compound, nomlabofusp. The designation is applicable for the use of nomlabofusp in the treatment of children and adults with Friedreich’s ataxia, a rare genetically driven neuro...
Shidlovski/iStock via Getty Images Larimar Therapeutics ( LRMR ) added ~38% in the premarket on Tuesday after the rare disease drug developer said that the U.S. FDA has granted Breakthrough Therapy Designation for its lead compound, nomlabofusp. The designation is applicable for the use of nomlabofusp in the treatment of children and adults with Friedreich’s ataxia, a rare genetically driven neurodegenerative disorder caused by the deficiency of a protein called frataxin. The company added that it continues to align with the FDA’s decision to use frataxin as a surrogate endpoint that could support a potential accelerated approval for nomlabofusp in the U.S. In this regard, Larimar ( LRMR ) expects to submit a Biologics License Application (BLA) for nomlabofusp in June, targeting a potential commercial rollout of the protein replacement therapy in H1 2027. The FDA's Breakthrough Therapy designation aims to expedite the development and review of treatments targeted at serious or life-threatening conditions. With the full features of the designation, a drug developer can receive intensive regulatory guidance and potentially be eligible for the FDA’s priority review for a treatment with the breakthrough therapy status. More on Larimar Therapeutics Larimar Therapeutics: The Market Is Mispricing A Potential Standard Of Care Larimar Therapeutics, Inc. (LRMR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Larimar Therapeutics, Inc. (LRMR) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Seeking Alpha’s Quant Rating on Larimar Therapeutics Historical earnings data for Larimar Therapeutics
Getty Images Donnelley Financial Solutions ( DFIN ) provided a good business update during its most recent quarter, with the company's move towards more recurring software revenue growth progressing well. Though there are still some areas to be skeptical, business performance was strong and gives investors some hope on what is to follow in the coming quarters. DFIN is a financial technology compan...
Getty Images Donnelley Financial Solutions ( DFIN ) provided a good business update during its most recent quarter, with the company's move towards more recurring software revenue growth progressing well. Though there are still some areas to be skeptical, business performance was strong and gives investors some hope on what is to follow in the coming quarters. DFIN is a financial technology company that provides risk and compliance solutions for enterprise customers. The company's solutions include services for regulatory filing, financial reporting, deal management (IPO and secondaries), ESG filings, and data security. In essence, the company's platform of offerings helps enterprises streamline their SEC filings and ensure regulatory compliance. Data by YCharts As seen in the chart above, DFIN has been subject to many periods of volatility, mostly revolving around the company's quarterly reports. Over the past 6+ months, however, the stock has been pressured due to the broader fear that traditional software applications will be rendered useless in a world dominated by GenAI applications. Sure, there are many risks around this thesis that DFIN is exposed to. Recent results might suggest the company is weathering the storm nicely. But fighting against bearish sentiment in this current market is proving to be challenging for many software companies. For now, I believe the recent positive move in shares post-earnings was more likely some shorts covering their positions rather than fundamental investors stepping in. Yes, trends are improving, but the current negative cloud across software investing makes it challenging to say the coast is clear. I remain on the sidelines waiting for another quarterly update and positive estimate revisions before getting comfortable with this investment. Financial Update During the company's most recent quarter , revenue grew an impressive 10.4% yoy to $172.5 million, beating consensus expectations by ~10%. One of the main drivers behind...
Deutsche Bank sees shares of Blue Owl Capital stagnating from here, citing slower fee-related earnings growth, as the private credit posterchild's struggles continue. Analyst Brian Bedell downgraded the stock to hold from buy. He also slashed his price target to $10 from $15, which implies downside of 4%. Shares of Blue Owl have plunged 52% over the past 12 months and 30% this year alone, swept up...
Deutsche Bank sees shares of Blue Owl Capital stagnating from here, citing slower fee-related earnings growth, as the private credit posterchild's struggles continue. Analyst Brian Bedell downgraded the stock to hold from buy. He also slashed his price target to $10 from $15, which implies downside of 4%. Shares of Blue Owl have plunged 52% over the past 12 months and 30% this year alone, swept up in an overall private credit sell-off amid fears that the sector could be cracking because of their exposure to software industry loans just as Wall Street tries to open the market up to retail investors. The stock also sank after it permanently restricted withdrawals from one of its retail-focused debt funds amid plans to wind down the portfolio. Blue Owl stock lost 2% on Tuesday morning. OWL 1Y mountain OWL 1Y chart Bedell wrote that his downgrade was driven by reductions in his forecasts for fee-related earnings related to his revised expectations for slower growth in retail private credit products. This, he said, stemmed from lower sales and higher redemption forecasts. "This said, we think the adverse headlines around its private credit business broadly are overdone, including around recent initiatives to deliver liquidity to investors in selected retail private credit products," he added. "However, we think these headlines and publicity may cause retail wealth redemption requests to rise at least modestly in some private credit products, while also driving slower sales, in at least the near-term and possibly for much of this year." Bedell noted that management has diversified Blue Owl in the past two to three years, helping to advance its growth outlook even further. But he added that shares of Blue Owl appear fairly valued at their current levels. "While we see both upside and downside risks to this view, we do not see a near-term catalyst to advance the shares, given a likely adverse sentiment overhang until the firm demonstrates sustained positive flows within its...